Browsing by Author "Ergan, Begum"

Now showing 1 - 5 of 5

Context Sensitive Links The Role of Aerolized Colistin in the Treatment of Hospital-Acquired Pneumonia: Experience of Multicenter From Turkey: Erratum (vol 44, pg e304, 2016)
(2018) Ekren, Pervin Korkmaz; Toreyin, Nur; Takir, Huriye Berk; Balci, Merih Kalamanoglu; Gaygisiz, Ummugulsum; Gursel, Gul; Ergan, Begum; Yalcin, Aslihan; Salturk, Cuneyt; Aydogdu, Muge; Ergun, Recai; Guven, Pinar; Ulubay, Gaye; Kaya, Aslihan Gurun; Celtik, Aygul; Uluer, Hatice; Bacakoglu, Feza; Sayiner, Abdullah; https://orcid.org/0000-0003-2478-9985; AAB-5064-2021
ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure
(2022) Oczkowski, Simon; Ergan, Begum; Bos, Lieuwe; Chatwin, Michelle; Ferrer, Miguel; Gregoretti, Cesare; Heunks, Leo; Frat, Jean-Pierre; Longhini, Federico; Nava, Stefano; Navalesi, Paolo; Ugurlu, Aylin Ozsancak; Pisani, Lara; Renda, Teresa; Thille, Arnaud W.; Winck, Joao Carlos; Windisch, Wolfram; Tonia, Thomy; Boyd, Jeanette; Sotgiu, Giovanni; Scala, Raffaele; 34649974
Background High-flow nasal cannula (HFNC) has become a frequently used noninvasive form of respiratory support in acute settings; however, evidence supporting its use has only recently emerged. These guidelines provide evidence-based recommendations for the use of HFNC alongside other noninvasive forms of respiratory support in adults with acute respiratory failure (ARF). Materials and methodology The European Respiratory Society task force panel included expert clinicians and methodologists in pulmonology and intensive care medicine. The task force used the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methods to summarise evidence and develop clinical recommendations for the use of HFNC alongside conventional oxygen therapy (COT) and noninvasive ventilation (NIV) for the management of adults in acute settings with ARF. Results The task force developed eight conditional recommendations, suggesting the use of 1) HFNC over COT in hypoxaemic ARF; 2) HFNC over NIV in hypoxaemic ARF; 3) HFNC over COT during breaks from NIV; 4) either HFNC or COT in post-operative patients at low risk of pulmonary complications; 5) either HFNC or NIV in post-operative patients at high risk of pulmonary complications; 6) HFNC over COT in nonsurgical patients at low risk of extubation failure; 7) NIV over HFNC for patients at high risk of extubation failure unless there are relative or absolute contraindications to NIV; and 8) trialling NIV prior to use of HFNC in patients with COPD and hypercapnic ARF. Conclusions HFNC is a valuable intervention in adults with ARF. These conditional recommendations can assist clinicians in choosing the most appropriate form of noninvasive respiratory support to provide to patients in different acute settings.
Evaluation of nephrotoxicity and prognosis in patients treated with colistin due to hospital-acquired pneumonia
(2017) Ulubay, Gaye; Korkmaz Ekren, Pervin; Toreyin, Zehra Nur; Berk Takir, Huriye; Kalamanoglu Balci, Merih; Gaygisiz, Ummugulsum; Gursel, Gul; Ergan, Begum; Yalcin, Aslihan; Saltürk, Cuneyt; Aydogdu, Muge; Ergun, Recai; Guven, Pinar; Gurun Kaya, Aslihan; Celtik, Aygul; Uluer, Hatice; Bacakoglu, Feza; Sayiner, Abdullah; 0000-0003-2478-9985; 29631525; AAB-5064-2021
Introduction: Colistimethate sodium (CMS) is frequently used in the treatment of nosocomial multidrug-resistant gram-negative infections. Nephrotoxicity is the most important side effect. The aim of this study is to evaluate the effect of colistin on nephrotoxicity and to assess prognosis in patients treated with CMS due to hospital-acquired pneumonia (HAP). Materials and Methods: Patients treated with CMS for HAP due to multidrug-resistant Pseudomonas aeruginosa or Acinetobacter baumannii were included in this cohort study. Results: We evaluated 281 patients treated with two different brands of CMS whose administration dose is different: imported (n=58, low dose/kg) and domestic (n=223, high dose/kg). Nephrotoxicity developed in 175 patients (62.3%). The median age (73 vs. 66 years, p=0.004) and mortality rates were higher (66.9% vs. 52.8%, p=0.022) in patients having nephrotoxicity. The patients receiving high dose/kg had higher nephrotoxicity rate (67.7% vs. 41.4%, p < 0.001). The clinical, bacteriological response and mortality rates of the whole group were 52.0%, 61.0%, 61.6%, respectively. The clinical and bacteriological response rates were similar in the different dose groups. Multivariate analysis showed that nephrotoxicity was associated with domestic brand depending on use of high dose (OR=3.97), advanced age (beta=0.29, p=0.008), male gender (OR=2.60), hypertension (OR=2.50), red blood cells transfusion (OR=2.54), absence of acute kidney injury (OR=10.19), risk stage of RIFLE (OR=11.9). Conclusion: Nephrotoxicity is associated with the use of high dose colistin, age, gender, hypertension, red blood cells replacement and RIFLE stage. The mortality rate is higher in patients developing nephrotoxicity.
Late Breaking Abstract - WEAning From NonInvasive Ventilation 'WEANIV' Study
(2020) Ugurlu, Aylin Ozsancak; Karakurt, Zuhal; Scala, Raffaele; Ozyilmaz, Ezgi; Ergan, Begum; Nava, Stefano; Dimarco, Fabiano; Tuncay, Eylem; Ciarleglio, Giuseppina; Hasan, Orhan Othman; Betti, Sara; Giuliani, Lisa
The Role of Aerolized Colistin in the Treatment of Hospital-Acquired Pneumonia: Experience of Multicenter From Turkey: Erratum (vol 44, pg e304, 2016)
(2018) Ekren, Pervin Korkmaz; Toreyin, Nur; Takir, Huriye Berk; Balci, Merih Kalamanoglu; Gaygisiz, Ummugulsum; Gursel, Gul; Ergan, Begum; Yalcin, Aslihan; Salturk, Cuneyt; Aydogdu, Muge; Ergun, Recai; Guven, Pinar; Ulubay, Gaye; Kaya, Aslihan Gurun; Celtik, Aygul; Uluer, Hatice; Bacakoglu, Feza; Sayiner, Abdullah; 0000-0003-2478-9985; AAB-5064-2021